The Effect of Exercise Intervention on Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD)

Sponsor
University of Liverpool (Other)
Overall Status
Unknown status
CT.gov ID
NCT01834300
Collaborator
Royal Liverpool University Hospital (Other), University of Surrey (Other), Imperial College London (Other), Royal Surrey County Hospital NHS Foundation Trust (Other)
60
7
2
75.9
8.6
0.1

Study Details

Study Description

Brief Summary

This project examines the effects of a 4 month structured exercise intervention program in patients with non-alcoholic fatty liver disease (NAFLD). We will examine changes in total and depot-specific (i.e.in different tissues, liver, muscle and pancreas)fat. We will correlate these with measurements of the insulin from the liver. The hypothesis is that by reducing fat in these specific depots we can reduce insulin resistance and prevent progression to diabetes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Unsupervised exercise training
  • Behavioral: Supervised exercise training
N/A

Detailed Description

  1. Exercise program: We are asking people to take part in a supervised exercise program for 4 months. This involves on average a weekly supervised exercise bout plus other unsupervised exercise bouts at home. We will ensure participants are physically able to embark on this by taking their medical history, physical examination and validated questionnaire (PARQ). This program is for the benefit on the patients' long term health.

  2. MR imaging to assess fat: occassionally these may pick up anomalies which require further investigation. A radiologist will screen the abdominal images and GP will be informed on anything requiring further investigation.

No radiation is received during MR imaging.

  1. Physiological studies: Patients will be asked to attend for 2 non-consecutive days before and after the exercise intervention. Regular blood samples will be required as apart of these investigations.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effects of Exercise Training on Visceral Fat, Insulin Sensitivity, β-cell Function and Triglyceride Kinetics in Patients With Non-alcoholic Fatty Liver Disease (NAFLD).
Study Start Date :
Feb 1, 2009
Actual Primary Completion Date :
Apr 1, 2013
Anticipated Study Completion Date :
Jun 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Control

Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.

Behavioral: Unsupervised exercise training
The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.

Experimental: lifestyle counseling and exercise

Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.

Behavioral: Supervised exercise training
Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.

Outcome Measures

Primary Outcome Measures

  1. Reduction in liver and muscle fat [4 months]

    Tissue triglyceride content, or steatosis, will be accurately and non-invasively quantified in vivo using localized proton magnetic resonance spectroscopy (1H MRS).

Secondary Outcome Measures

  1. Changes in liver function tests [4 months]

    Biochemial measurements of the liver enzymes will be measured pre and post intervention period

  2. Changes in lipid profiles [4 months]

    Total cholesterol, triglyceride and high density lipoprotien concentrations in fasting state will be measured pre and post intervention period.

  3. Changes in body weight and anthropometric measurements [4 months]

    Body weight and waist to hip ratio will be measured pre and post intervention period.

  4. Hepatic insulin sensitivity [4 months]

    Half of the study cohort i.e. 30 individuals,15 exercise and 15 controls, will have peripheral and hepatic insulin sensitivity determined using a two-stage hyperinsulinaemic, euglycaemic clamp and use of deuterated glucose (2H2-glucose

  5. VLDL-TG kinetics [4 months]

    The other half of the study cohort i.e. 30 individuals, 15 exercise and 15 controls, will have VLDL1 and VLDL2 TG kinetics determined using 5H2 glycerol bolus.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Sedentary, non smoking, male subjects,

  • Alcohol consumption men <21 units/week,

  • BMI 27-35. (Lean individuals do not suffer from NAFLD, so are not suitable for this study. Conversely, we are restricted to a maximum BMI of 35 due to the size limitations of the MR scanner.)

  • A clinical diagnosis of NAFLD based upon the following criteria: i) exclusion of other causes of liver disease i.e. negative Hepatitis B and C serology, a negative auto-immune profile and normal caeruloplasmin concentrations, ii) Ultrasound appearances suggestive of a fatty, echo-bright liver with no evidence of cirrhosis (in some cases, the diagnosis will have been confirmed histologically after liver biopsy.

  • Being willing to engage and motivated to follow an exercise program.

Exclusion Criteria:
  • Prescription of corticosteroids, amiodarone, tamoxifen, methotrexate (drugs known to cause secondary steatohepatitis) or fibrates. Statin is Ok as long as the patients are on stable therapy for a while, if changed then the patient will be excluded.

  • Alcohol consumption for men 21 units/week.

  • A contraindication to exercise (such as unstable ischaemic heart disease),

  • Type 2 diabetes (type 2 diabetes patients are excluded so that we are examining the involvement of insulin resistance at a reversible stage before β-cell failure has occurred).

  • Patients who are on medications that will interact with GTN (glyceryl trinitrate) will be excluded from the GTN dilatation (endothelial independent NO mediated function) aspect of the study.

  • Individuals who suffer from claustrophobia and have metal implants will be excluded from the MRI aspect of the study.

  • Patients who smoke will also be excluded from the study.

  • Total cholesterol >7

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal Surrey County Hospital Guildford Surrey United Kingdom GU16 7UJ
2 University of Surrey Guildford Surrey United Kingdom GU27WG
3 John Moores University Liverpool United Kingdom L3 2ET
4 University of Liverpool Liverpool United Kingdom L69 3GE
5 Royal Liverpool University Hospital Liverpool United Kingdom L7 8XP
6 Liverpool University Liverpool United Kingdom L9 7AL
7 Imperial College London London United Kingdom W12 0HS

Sponsors and Collaborators

  • University of Liverpool
  • Royal Liverpool University Hospital
  • University of Surrey
  • Imperial College London
  • Royal Surrey County Hospital NHS Foundation Trust

Investigators

  • Study Director: Daniel Cuthbertson, BSc PhD MRCP, University of Liverpool
  • Principal Investigator: Fariba Shojaee-Moradie, BSc PhD, University of Surrey

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Daniel Cuthbertson, Senior Lecturer and Honorary Consultant Physician, University of Liverpool
ClinicalTrials.gov Identifier:
NCT01834300
Other Study ID Numbers:
  • 09/H1008/1
First Posted:
Apr 17, 2013
Last Update Posted:
Sep 17, 2014
Last Verified:
Sep 1, 2014
Keywords provided by Daniel Cuthbertson, Senior Lecturer and Honorary Consultant Physician, University of Liverpool
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 17, 2014